Table 3.
Predictors of poor outcome (SIS≤70) at days 30, 90, 180 and 365 after stroke. Data are either unadjusted or adjusted for NIHSS, age, and titer of anti-TT antibodies.
| Fazekas≥3 | abMBP*75% | abPLP*75% | abTT**75% | ||||||
|---|---|---|---|---|---|---|---|---|---|
| OR (CI) | P | OR (CI) | P | OR (CI) | P | OR (CI) | P | ||
| day 30 | 1.654 (0.582–4.700) | NS | 1.054 (0.388–2.862) | NS | 0.688 (0.253–1.866) | NS | 1.084 (0.399–2.940) | NS | |
| Adj. for: |
NIHSS | 2.064 (0.590–7.224) | NS | 1.595 (0.476–5.345) | NS | 2.103 (0.565–7.831) | NS | 0.608 (0.174–2.128) | NS |
| NIHSS, age | 1.808 (0.438–6.657) | NS | 1.459 (0.430–4.949) | NS | 2.352 (0.599–9.229) | NS | 0.690 (0.191–2.486) | NS | |
| NIHSS, age, abTT | 1.801 (0.426–7.620) | NS | 1.448 (0.421–4.980) | NS | 2.356 (0.586–9.467) | NS | --- | --- | |
| day 90 | 1.980 (0.674–5.813) | NS | 1.524 (0.495–4.687) | NS | 0.471 (0.136–1.633) | NS | 0.635 (0.197–2.048) | NS | |
| Adj. for: |
NIHSS | 2.560 (0.672–9.750) | 0.168 | 4.135 (0.951–17.990) | 0.058 | 0.754 (0.184–3.095) | NS | 0.579 (0.149–2.248) | NS |
| NIHSS, age | 1.995 (0.466–8.547) | NS | 3.578 (0.811–15.786) | 0.092 | 0.760 (0.179–3.231) | NS | 0.783 (0.188–3.266) | NS | |
| NIHSS, age, abTT | 1.920 (0.385–9.583) | NS | 3.533 (0.767–16.261) | 0.105 | 0.727 (0.169–3.118) | NS | --- | --- | |
| day 180 | 2.061 (0.683–6.217) | 0.199 | 0.771 (0.215–2.757) | NS | 0.750 (0.209–2.686) | NS | 1.121 (0.333–3.781) | NS | |
| Adj. for: |
NIHSS | 2.448 (0.658–9.105) | 0.182 | 3.938 (0.696–22.292) | 0.121 | 1.086 (0.234–5.047) | NS | 1.371 (0.322–5.845) | NS |
| NIHSS, age | 1.662 (0.392–7.045) | NS | 4.184 (0.741–23.625) | 0.105 | 1.559 (0.303–8.019) | NS | 1.760 (0.393–7.879) | NS | |
| NIHSS, age, abTT | 1.968 (0.325–11.904) | NS | 4.509 (0.793–25.632) | 0.089 | 1.531 (0.296–7.926) | NS | --- | --- | |
| day 365 | 2.519 (0.0844–7.517) | 0.098 | 4.500 (1.133–17.878) | 0.033 | 1.095 (0.293–4.097) | NS | 0.958 (0.263–3.492) | NS | |
| Adj. for: |
NIHSS | 3.190 (0.866–11.743) | 0.081 | 4.957 (1.039–23.659) | 0.045 | 1.011 (0.225–4.550) | NS | 1.203 (0.267–5.419) | NS |
| NIHSS, age | 2.523 (0.613–10.390) | 0.200 | 5.189 (1.034–26.052) | 0.045 | 1.052 (0.226–4.890) | NS | 1.267 (0.268–5.990) | NS | |
| NIHSS, age, abTT | 3.147 (0.513–19.296) | NS | 6.077 (1.090–33.888) | 0.040 | 1.026 (0.217–4.846) | NS | --- | --- | |
SIS=stroke impact scale,
*
antibody titers to MBP and PLP are quantified by relative absorbance,
**
antibody titers to TT are quantified by IU/mL, abMBP 75%=antibody titer to myelin basic protein >75th percentile for stroke patients at that time point; abPLP 75%=antibody titer to proteolipid protein >75th percentile for stroke patients at that time point, abTT 75%=antibody titer to tetanus toxoid >75th percentile for stroke patients at that time point, abTT=antibody titer to tetanus toxoid, NIHSS=National Institutes of Health Stroke Scare, NS=not significant (P>0.200)